{
  "id": "601c3fc21cb411341a000019",
  "type": "factoid",
  "question": "Which receptor is blocked by Finerenone?",
  "ideal_answer": "Finerenone is a nonsteroidal mineralocorticoid receptor antagonist.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28025025",
    "http://www.ncbi.nlm.nih.gov/pubmed/32088716",
    "http://www.ncbi.nlm.nih.gov/pubmed/28926607",
    "http://www.ncbi.nlm.nih.gov/pubmed/30171161",
    "http://www.ncbi.nlm.nih.gov/pubmed/30356804",
    "http://www.ncbi.nlm.nih.gov/pubmed/26203193",
    "http://www.ncbi.nlm.nih.gov/pubmed/26634965",
    "http://www.ncbi.nlm.nih.gov/pubmed/29437893",
    "http://www.ncbi.nlm.nih.gov/pubmed/29779093",
    "http://www.ncbi.nlm.nih.gov/pubmed/31665733",
    "http://www.ncbi.nlm.nih.gov/pubmed/32945624",
    "http://www.ncbi.nlm.nih.gov/pubmed/28320854",
    "http://www.ncbi.nlm.nih.gov/pubmed/32729974",
    "http://www.ncbi.nlm.nih.gov/pubmed/26325557",
    "http://www.ncbi.nlm.nih.gov/pubmed/29668577",
    "http://www.ncbi.nlm.nih.gov/pubmed/33099609",
    "http://www.ncbi.nlm.nih.gov/pubmed/30825073",
    "http://www.ncbi.nlm.nih.gov/pubmed/26902493",
    "http://www.ncbi.nlm.nih.gov/pubmed/33179798",
    "http://www.ncbi.nlm.nih.gov/pubmed/31583611",
    "http://www.ncbi.nlm.nih.gov/pubmed/33107592",
    "http://www.ncbi.nlm.nih.gov/pubmed/31283930",
    "http://www.ncbi.nlm.nih.gov/pubmed/24621652",
    "http://www.ncbi.nlm.nih.gov/pubmed/25678098",
    "http://www.ncbi.nlm.nih.gov/pubmed/28577743",
    "http://www.ncbi.nlm.nih.gov/pubmed/26095025",
    "http://www.ncbi.nlm.nih.gov/pubmed/27431783",
    "http://www.ncbi.nlm.nih.gov/pubmed/32890415",
    "http://www.ncbi.nlm.nih.gov/pubmed/32910349",
    "http://www.ncbi.nlm.nih.gov/pubmed/31655812"
  ],
  "snippets": [
    {
      "text": "Finerenone (FIN), a novel, nonsteroidal, potent, and selective mineralocorticoid receptor antagonist, improves endothelial dysfunction through enhancing nitric oxide (NO) bioavailability and decreasing superoxide anion levels due to an upregulation in vascular and renal superoxide dismutase activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32088716",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Here, we investigated metabolic effects of the novel non-steroidal MRA finerenone (FIN) in a mouse model of high-fat diet (HFD)-induced obesity and the signaling pathways activated by MR antagonism at level of interscapular brown adipose tissue (iBAT).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32729974",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVES: To evaluate the effects of aldosterone antagonists (selective (eplerenone), non-selective (spironolactone or canrenone), or non-steroidal mineralocorticoid antagonists (finerenone)) in adults who have CKD with proteinuria (nephrotic and non-nephrotic range) on: patient-centred endpoints including kidney failure (previously know as end-stage kidney disease (ESKD)), major cardiovascular events, and death (any cause); kidney function (proteinuria, estimated glomerular filtration rate (eGFR), and doubling of serum creatinine); blood pressure; and adverse events (including hyperkalaemia, acute kidney injury, and gynaecomastia).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33107592",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For example, the novel nonsteroidal MRA finerenone has a balanced distribution between the heart and kidney compared with spironolactone, which is preferentially concentrated in the kidneys.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33099609",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Other nonsteroidal MRA such as apararenone, finerenone, AZD9977, and LY2623091 are in different clinical trials in patients with hypertension suffering from renal or hepatic fibrotic diseases.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33179798",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "(-)-Finerenone is a nonsteroidal mineralocorticoid receptor antagonist currently in phase III clinical trials for the treatment of chronic kidney disease in type 2 diabetes. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32890415",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mineralocorticoid Receptor Antagonists: a Comprehensive Review of Finerenone.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32910349",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "PURPOSE OF REVIEW: We aim to review the mechanism of action and safety profile of mineralocorticoid receptor antagonists (MRAs) and discuss the differences between selective and non-selective MRAs. More specifically, finerenone is a new medication that is currently under investigation for its promising cardiovascular and nephrological effects.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32910349",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " A new selective MRA named finerenone (originally BAY 94-8862) has shown promising results in several trials (ARTS-HF and ARTS-DN) and smaller studies. Finerenone may have a dose-dependent benefit over older MRAs, decreasing rates of albuminuria and levels of BNP and NT-ProBNP without causing a significant increase in serum potassium levels.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32910349",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Mineralocorticoid receptor antagonism by finerenone is sufficient to improve function in preclinical muscular dystrophy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32945624",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31283930",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A mouse model of cardiac fibrosis induced by short-term isoproterenol injection was used to compare the nonsteroidal MRA finerenone and the steroidal MRA eplerenone in equi-efficient systemic MR blocking dosages.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29437893",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Finerenone is a novel selective nonsteroidal mineralocorticoid receptor antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28577743",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVES: Finerenone is a selective, non-steroidal mineralocorticoid receptor antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29779093",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVES: Finerenone\u00a0(BAY 94-8862) is a selective, nonsteroidal mineralocorticoid receptor antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30825073",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24621652",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "isease. Finerenone is a novel, non-steroidal, selective mineralocorticoid-receptor antagonist which has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD), while revealing only a low risk of hyperkalem",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31655812",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkale",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31665733",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AIMS: Finerenone (BAY 94-8862) is a novel non-steroidal mineralocorticoid receptor antago",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28025025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Finerenone (BAY\u00a094-8862) is a potent non-steroidal, selective mineralocorticoid receptor antagonist being developed for the treatment of patients with type\u00a02 diabetes and chronic kidne",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31583611",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: The novel nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone holds promise to be safe and efficient in the treatment of patients with heart failure and/or chronic kidn",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28926607",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: The non-steroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) has been used to treat chronic heart failure (CHF) with reduced ejection fraction",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29668577",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Finerenone, a novel nonsteroidal MR antagonist, is presently being evaluated in two clinical phase IIb trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26203193",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28320854",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Mineralocorticoid receptor antagonism has shown to be helpful against renal IR consequences; however, the potential benefit of novel nonsteroidal mineralocorticoid receptor antagonists such as finerenone has to be further explored.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28320854",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The Munich Wistar Fr\u00f6mter (MWF) rat is a model of chronic kidney disease (CKD), which exhibits endothelial dysfunction associated to low nitric oxide availability. We hypothesize that the new highly selective, non-steroidal mineralocorticoid receptor (MR) antagonist, finerenone, reverses both endothelial dysfunction and microalbuminuria. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30356804",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "OBJECTIVE: To evaluate the safety and efficacy of different oral doses of the nonsteroidal mineralocorticoid receptor antagonist finerenone, given for 90 days to patients with diabetes and high or very high albuminuria who are receiving an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26325557",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two months after coronary artery ligation causing MI, mice with VSMC-specific MR deletion (MI-MR(SMKO)) and mice treated with the MR antagonist finerenone (MI-fine) had improved left ventricular compliance and elastance when compared with infarcted control mice (MI-CTL), as well as reduced interstitial fibrosis. Importantly, the coronary reserve assessed by magnetic resonance imaging was preserved (difference in myocardial perfusion before and after induction of vasodilatation, mL mg(-1) min(-1): MI-CTL: 1.1 \u00b1 0.5, nonsignificant; MI-MR(SMKO): 4.6 \u00b1 1.6 [P<0.05]; MI-fine: 3.6 \u00b1 0.7 [P<0.01]).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26902493",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "AIMS: To investigate the safety and potential efficacy of the novel non-steroidal mineralocorticoid receptor antagonist finerenone in patients with worsening chronic heart failure and reduced left ventricular ejection fraction (HFrEF) and at high risk of hyperkalaemia and worsening renal dysfunction.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25678098",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26095025",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Finerenone is a novel nonsteroidal MRA, with higher selectivity toward the mineralocorticoid receptor (MR) compared to spironolactone and stronger MR-binding affinity than eplerenone.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26095025",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, finerenone (BAY 94-8862) has emerged as a next-generation non-steroidal dihydropyridine-based MR antagonist designed to minimize off-target effects while maintaining potent efficacy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26634965",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27431783",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Finerenone (BAY 94-8862) is a nonsteroidal mineralocorticoid receptor antagonist in development for the treatment of diabetic kidney disease. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27431783",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171161",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Mass balance and biotransformation of finerenone, a nonsteroidal mineralocorticoid receptor antagonist, were investigated in four healthy male volunteers following a single oral administration of 10 mg (78 \u03bcCi) of [14C]finerenone and compared with data from studies in dogs and rats. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30171161",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "mineralocorticoid"
}